Lucence Diagnostics is a genomic medicine company founded to fulfill the vision of a world without avoidable cancer deaths. The company invents non-invasive blood tests that improve cancer detection and treatment selection. Lucence’s tests target the most common cancers in Asia using its proprietary amplicon-based sequencing technology and AI platform. Lucence is headquartered in San Francisco and Singapore, with offices in Suzhou and Hong Kong. Its services are delivered worldwide through an accredited central laboratory. Visit www.lucencedx.com for more information.